Tofacitinib for elderly onset hemophagocytic lymphohistiocytosis with gene mutations: a case report

References

1	P La Rosée, A Horne, M Hines, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465-2477.
2	V Lougaris, M Baronio, A Castagna, et al. Paediatric MAS/HLH caused by a novel monoallelic activating mutation in p110δ. Clin Immunol. 2020;219:108543.
3	IK Chinn, OS Eckstein, EC Peckham-Gregory, et al. Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood. 2018;132(1):89-100.
4	K Wei?ert, S Ammann, T K?gl, et al. Adoptive T cell therapy cures mice from active hemophagocytic lymphohistiocytosis (HLH). EMBO Mol Med. 2022;14(12):e16085.
5	S Albeituni, KC Verbist, PE Tedrick, et al. Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis. Blood. 2019;134(2):147-159.
6	A Ahmed, SA Merrill, F Alsawah, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 2019;6(12):e630-e637.
7	J Wang, R Zhang, X Wu, et al. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial. Br J Haematol. 2021;193(4):761-768.
8	Q Zhang, A Wei, HH Ma, et al. A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis. Haematologica. 2021;106(7):1892-1901.
9	D Zhou, X Huang, M Xie, et al. Ruxolitinib combined with dexamethasone in adult patients with newly diagnosed hemophagocytic lymphohistiocytosis: a single-center pilot trial. Am J Hematol. 2023;98(5):E106-E109.
10	N Ruperto, HI Brunner, O Synoverska, et al. Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG). Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet. 2021;398(10315):1984-1996.